Is Iovance Biotherapeutics Inc (IOVA) a risky stock?
As of July 21, 2026, Clavix grades Iovance Biotherapeutics Inc (IOVA) C+ for risk, a composite score of 62 out of 100 on an A+ to F scale, which puts IOVA in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind IOVA's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how IOVA scores on each, as of July 21, 2026.
What's moving IOVA's risk right now
Company-specific signals Clavix flags behind IOVA's current grade, drawn from recent news and filings as of July 21, 2026.
Iovance shares have climbed 74% this year, though they remain below Wall Street's average price target. The rally is tied to the U.S. and Canadian rollout of Amtagvi and continued revenue growth.
Iovance won FDA clearance to begin trials of next-generation therapy IOV-5001, and Australia approved Amtagvi, where melanoma rates are the world's highest. Shares jumped 9.4% on the Australian nod.
rating H.C. Wainwright kept its Buy rating and $9 price target on Iovance, pointing to Amtagvi's improving sales trend as the main reason for its bullish view.
What a C+ grade means
On the Clavix A+ to F scale, IOVA's composite of 62 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell IOVA or any security. Grades are risk indicators, not predictions of return. Data may be delayed.